Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Other Liver Disease by Year
Other Liver Disease (Harvoni, Vosevi, Viread, Hepcludex, Sovaldi & Livdelzi prior to Q1 2026) — Rest of World sales ($M) ($M)
Gilead Sciences Other Liver Disease: $69M in FY2025, down 5.5% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other Liver Disease (Harvoni, Vosevi, Viread, Hepcludex, Sovaldi & Livdelzi prior to Q1 2026) — Rest of World sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 69 | -5.5% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 73 | -12.0% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 83 | -33.1% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 124 | – | Form 10-K (filed 2025-02-28) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Other Liver Disease ($M), annual FY2022–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-other-row
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.